BNP Paribas Financial Markets
VRDN icon

BNP Paribas Financial Markets’s Viridian Therapeutics VRDN Stock Holding History

BNP Paribas Financial Markets’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.6M Buy
1,012,138
+745,739
+280% +$12M 0.01% 1278
2026
Q1 		$5.21M Sell
266,399
-250,999
-49% -$7.45M ﹤0.01% 1989
2025
Q4 		$16.1M Buy
517,398
+275,091
+114% +$7.54M 0.01% 1318
2025
Q3 		$5.23M Buy
242,307
+52,078
+27% +$939K ﹤0.01% 1944
2025
Q2 		$2.66M Buy
190,229
+51,365
+37% +$697K ﹤0.01% 2278
2025
Q1 		$1.87M Sell
138,864
-64,989
-32% -$1.11M ﹤0.01% 2405
2024
Q4 		$3.91M Buy
+203,853
New +$4.43M ﹤0.01% 1944
2022
Q4 		– Sell
-35,445
Closed -$727K – 4652
2022
Q3 		$727K Buy
+35,445
New +$637K ﹤0.01% 2717
2020
Q3 		– Sell
-1
Closed -$17 – 4293
2020
Q2 		$17 Sell
1
-9
-90% -$102 ﹤0.01% 4257
2020
Q1 		$69 Hold
10
– – ﹤0.01% 4230
2019
Q4 		$74 Sell
10
-191
-95% -$1.96K ﹤0.01% 4341
2019
Q3 		$2.21K Hold
201
– – ﹤0.01% 4351
2019
Q2 		$6.19K Sell
201
-167
-45% -$6.7K ﹤0.01% 4207
2019
Q1 		$15.4K Buy
368
+338
+1,127% +$15.3K ﹤0.01% 3958
2018
Q4 		$1.36K Sell
30
-61
-67% -$3.53K ﹤0.01% 3877
2018
Q3 		$7.59K Buy
91
+24
+36% +$2.26K ﹤0.01% 3876
2018
Q2 		$6.43K Sell
67
-248
-79% -$26.2K ﹤0.01% 3981
2018
Q1 		$33.1K Buy
315
+120
+62% +$13K ﹤0.01% 3755
2017
Q4 		$30.6K Buy
195
+113
+138% +$14.4K ﹤0.01% 3873
2017
Q3 		$11.3K Sell
82
-6
-7% -$1.01K ﹤0.01% 3835
2017
Q2 		$17.1K Buy
+88
New +$14.9K ﹤0.01% 3746

Other funds holding VRDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Financial Markets's VRDN Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Viridian Therapeutics (VRDN) stake by 280% in Q2 2026, buying an estimated $12M and bringing the position to 1,012,138 shares worth $18.6M. The position accounts for 0.01% of the portfolio, ranked #1278.

BNP Paribas Financial Markets first reported a position in VRDN in Q2 2017 and has held it in 21 quarters since. 193 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • BNP Paribas Financial Markets held 1,012,138 shares of Viridian Therapeutics worth $18.6M as of Q2 2026.
  • BNP Paribas Financial Markets bought 745,739 Viridian Therapeutics shares in Q2 2026, an estimated $12M.
  • Viridian Therapeutics made up 0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #1278 holding.
  • BNP Paribas Financial Markets first reported a position in Viridian Therapeutics in Q2 2017 and has held it in 21 quarters since.
  • 193 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.